Leap Therapeutics, Inc. announced the promotion of Jason Baum, Ph.D. to Chief Scientific Officer, effective April 1, 2023. Jason Baum has served as company's Vice President and Head of Translational Research since August 2020.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.51 USD | -2.33% | -8.73% | -39.45% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-39.45% | 98.34M | |
+8.63% | 115B | |
+13.17% | 107B | |
-12.76% | 22.31B | |
-3.99% | 21.6B | |
-7.19% | 18.23B | |
-39.93% | 17.62B | |
+6.67% | 14.26B | |
+33.90% | 12.37B | |
-28.60% | 8.28B |
- Stock Market
- Equities
- LPTX Stock
- News Leap Therapeutics, Inc.
- Leap Therapeutics, Inc. Announces the Promotion of Jason Baum to Chief Scientific Officer, Effective April 1, 2023